List of RNAi Companies in South Korea - 2

Search through the full list with powerful filtering options

Company	About
MDimune Seoul, Korea	MDimune - The ultimate goal of MDimune Inc. is to provide an innovative platform technology that can revolutionize the paradigm of human therapeutics by achieving target-specific delivery of effective drugs. The precision of this novel technology will enable safer and more effective treatments of many debilitating human diseases and bring hope to patients.
OliX Pharmaceuticals Gyeonggi, Korea	OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.

Company

About

MDimune

Seoul, Korea

MDimune - The ultimate goal of MDimune Inc. is to provide an innovative platform technology that can revolutionize the paradigm of human therapeutics by achieving target-specific delivery of effective drugs. The precision of this novel technology will enable safer and more effective treatments of many debilitating human diseases and bring hope to patients.

OliX Pharmaceuticals

Gyeonggi, Korea

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.